Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9–26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) v...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, E. D., Giuliano, A. R., de Hoon, J., Iversen, O.-E., Joura, E. A., Restrepo, J., Van Damme, P., Vandermeulen, C., Ellison, M. C., Krick, A., Shields, C., Heiles, B., Luxembourg, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806635/
https://www.ncbi.nlm.nih.gov/pubmed/29211620
http://dx.doi.org/10.1080/21645515.2017.1403700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806635/
https://www.ncbi.nlm.nih.gov/pubmed/29211620
http://dx.doi.org/10.1080/21645515.2017.1403700

Ejemplares similares